Incannex Healthcare (ASX: IHL) has announced it will acquire APIRx Pharmaceutical USA in an all scrip (share consideration) deal to affirm its position as a global leader in the fields of cannabinoid, psychedelic and combination pharmaceuticals.
Highlights: APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain,.